Market Place
Sourcing Support
Data For Adults With Hypoparathyroidism Treated With TransCon PTH
30 Sep 2024 //
GLOBENEWSWIRE
Ascendis Pharma Submits BLA For TransCon hGH
30 Sep 2024 //
GLOBENEWSWIRE
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
19 Sep 2024 //
GLOBENEWSWIRE
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
18 Sep 2024 //
GLOBENEWSWIRE
Ascendis` Dwarfism Drug Shows Growth Acceleration In Phase 3
18 Sep 2024 //
PRESS RELEASE
Ascendis To Present IL-Believe Trial Results For Ovarian Cancer At ESMO
13 Sep 2024 //
GLOBENEWSWIRE
Ascendis Pharma Gets US Orphan Drug Exclusivity For YORVIPATH
11 Sep 2024 //
GLOBENEWSWIRE
Ascendis Pharma Reports Second Quarter 2024 Financial Results
03 Sep 2024 //
GLOBENEWSWIRE
Ascendis Pharma, Royalty Pharma Enter $150M Royalty Funding Agreement
03 Sep 2024 //
GLOBENEWSWIRE
Ascendis Pharma To Report Q2 2024 Results On September 3, 2024
28 Aug 2024 //
GLOBENEWSWIRE
MBX Files For IPO To Fund Phase 3 Of Yorvipath Challenger
26 Aug 2024 //
FIERCE BIOTECH
Ascendis Pharma`s hormone disorder therapy gets US approval
13 Aug 2024 //
REUTERS
FDA Approves YORVIPATH For Adult Hypoparathyroidism Treatment
12 Aug 2024 //
GLOBENEWSWIRE
Phase 2 ACcomplisH Trial Data On TransCon CNP In Achondroplasia Presented
24 Jun 2024 //
GLOBENEWSWIRE
Ascendis Pharma: Participating In Goldman Sachs Conference
04 Jun 2024 //
GLOBENEWSWIRE
Ascendis` IL-Believe Trial New Data, Updated Results At ASCO 2024
03 Jun 2024 //
GLOBENEWSWIRE
Ascendis Spotlights TransCon„ Portfolio At ENDO 2024
30 May 2024 //
GLOBENEWSWIRE
Significant Improvements in RFR for Adults Chronic Hypoparathyroidism
15 May 2024 //
PHARMIWEB
Ascendis must wait 3 more months for FDA verdict on TransCon PTH
15 May 2024 //
FIERCE PHARMA
Ascendis Announces FDA Extension For TransCon PTH Hypoparathyroidism Review
14 May 2024 //
GLOBENEWSWIRE
Sustained Renal Function Improvements In Hypoparathyroidism With TransCon PTH
13 May 2024 //
GLOBENEWSWIRE
TransCon PTH Hypoparathyroidism Data At ECE 2024
09 May 2024 //
GLOBENEWSWIRE
Ascendis Pharma Reports First Quarter 2024 Financial Results
02 May 2024 //
GLOBENEWSWIRE
Ascendis Pharma Reports Q1 2024 Results on May 2
25 Apr 2024 //
GLOBENEWSWIRE
UK MHRA Approves YORVIPATH for Hypoparathyroidism
24 Apr 2024 //
GLOBENEWSWIRE
Ascendis to Participate in the Leerink Partners Global Biopharma Conference 2024
04 Mar 2024 //
GLOBENEWSWIRE
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Conference
07 Feb 2024 //
GLOBENEWSWIRE
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
07 Feb 2024 //
GLOBENEWSWIRE
Ascendis Pharma Launches 2nd TransCon Product
31 Jan 2024 //
GLOBENEWSWIRE
Ascendis Pharma to Report Full Year 2023 Financial Results
31 Jan 2024 //
GLOBENEWSWIRE
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets
29 Jan 2024 //
GLOBENEWSWIRE
Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma
08 Jan 2024 //
GLOBENEWSWIRE
Vector Pharma FZCO Announce Agreement with Ascendis for Skytrofa
08 Jan 2024 //
GLOBENEWSWIRE
Specialised Therapeutics, Ascendis to commercialise endocrinology therapies
08 Jan 2024 //
BIOSPECTRUM ASIA
Specialised Therapeutics signs exclusive agreement with Ascendis Pharma
07 Jan 2024 //
PR NEWSWIRE
Ascendis Pharma Introduces Vision 2030
07 Jan 2024 //
GLOBENEWSWIRE
Ascendis to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
28 Dec 2023 //
GLOBENEWSWIRE
Significant Health Achieved in Children Treated with Navepegritide
20 Dec 2023 //
GLOBENEWSWIRE
TransCon Achieved Superior Outcomes Compared to Placebo in Ph 3 foresiGHt Trial
19 Dec 2023 //
GLOBENEWSWIRE
FDA Accepts for Review Resubmitted NDA for TransCon PTH
11 Dec 2023 //
GLOBENEWSWIRE
Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
29 Nov 2023 //
GLOBENEWSWIRE
Ascendis sells Japan rights to Skytrofa, 2 other drugs for $70M
29 Nov 2023 //
FIERCE BIOTECH
Ascendis Pharma Announces European Commission Approval of YORVIPATH
20 Nov 2023 //
GLOBENEWSWIRE
Ascendis Pharma Resubmits NDA for TransCon„¢ PTH to the U.S. FDA
15 Nov 2023 //
GLOBENEWSWIRE
Ascendis Pharma Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results
31 Oct 2023 //
GLOBENEWSWIRE
Ascendis Presents Updated and New TransCon Monotherapy
26 Oct 2023 //
GLOBENEWSWIRE
Ascendis Pharma Presents TransCon Phase 3 Data at ASBMR 2023
16 Oct 2023 //
GLOBENEWSWIRE
Ascendis Presents TransCon™ PTH Data at the Association Annual Meeting
02 Oct 2023 //
PRESS RELEASE
Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon
23 Sep 2023 //
GLOBENEWSWIRE
Ascendis Pharma Launches SKYTROFA in Germany
15 Sep 2023 //
GLOBENEWSWIRE
Ascendis Pharma Receives Positive CHMP Opinion for TransCon
14 Sep 2023 //
GLOBENEWSWIRE
Ascendis and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
05 Sep 2023 //
GLOBENEWSWIRE
New Post Hoc Analysis Showed Substantial Improvement in Observed eGFR
05 Sep 2023 //
GLOBENEWSWIRE
Ascendis Pharma Reports Second Quarter 2023 Financial Results
05 Sep 2023 //
GLOBENEWSWIRE
Ascendis Pharma A/S Announces Three Upcoming Investor Presentations
24 Aug 2023 //
GLOBENEWSWIRE
Ascendis Pharma to Report Second Quarter 2023 Financial Results
15 Aug 2023 //
GLOBENEWSWIRE
Ascendis presents additional data for TransCon PTH
20 Jun 2023 //
CLINICAL TRIALS ARENA
One-Year Data from Ph 3 Trial of TransCon PTH in Adults with Hypoparathyroidism
17 Jun 2023 //
GLOBENEWSWIRE
